The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Fibrolamellar carcinoma registry: Opportunities and challenges.
 
Layal Al Mahmasani
No Relationships to Disclose
 
Marinela Capanu
No Relationships to Disclose
 
Kurt Losert
No Relationships to Disclose
 
Maeve Aine Lowery
Consulting or Advisory Role - AstraZeneca; Roche/Genentech; SERVIER
Research Funding - Astellas Pharma (Inst); Basilea (Inst); Exelixis (Inst); Genuity Science (Inst); Legend Biotech (Inst); MSD (Inst); Zymeworks (Inst)
 
Martina Hennessy
No Relationships to Disclose
 
Mathew Ray
No Relationships to Disclose
 
Suzanne Chambers
No Relationships to Disclose
 
Amin Yaqubie
No Relationships to Disclose
 
Andrew Zarski
No Relationships to Disclose
 
Imane H. El Dika
No Relationships to Disclose
 
Joseph S. Light
No Relationships to Disclose
 
Michael P. La Quaglia
No Relationships to Disclose
 
Eileen M. O'Reilly
Consulting or Advisory Role - Abbvie (I); AstraZeneca; Autem Medical (I); Berry Genomics (I); BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Eisai (I); Exelixis (I); Genentech/Roche (I); Ipsen; J-Pharma (I); Merck; Merus; Novartis; QED Therapeutics (I); SERVIER (I); Tempus; Vector Health (I); Yiviva (I)
Research Funding - Agenus (Inst); Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Digestive Care (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Yiviva (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Abbvie; AstraZeneca; Autem Medical; Berry Genomics; BioNtech (I); Boehringer Ingelheim (I); Bristol-Myers Squibb/Medarex (I); Eisai; Exelixis; Ipsen; J-Pharma; Merck Serono (I); Merus NV (I); Neogene Therapeutics (I); Novartis (I); QED Therapeutics; Roche/Genentech; Servier; Tempus (I); Vector Health; Yiviva
Research Funding - Agenus (Inst); Arcus Ventures (Inst); AstraZeneca (Inst); BioNtech (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Genentech/Roche (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Pertzye (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Yiviva (Inst)